Entera Bio adds EB613 Phase 3 presentation at ASBMR meeting

Entera Bio said an additional poster on the study design for its planned Phase 3 registrational trial of EB613 will be presented at the ASBMR 2026 Annual Meeting in Boston. The company also said a separate Phase 2 EB613 presentation was selected for the meeting.